Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$33.11 USD
+0.26 (0.79%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $33.13 +0.02 (0.06%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$33.11 USD
+0.26 (0.79%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $33.13 +0.02 (0.06%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum D VGM
Zacks News
Delcath Systems, Inc. (DCTH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Delcath Systems (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Tandem Diabetes Care, Inc. (TNDM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down -21.69% in 4 Weeks, Here's Why Tandem Diabetes Care (TNDM) Looks Ripe for a Turnaround
by Zacks Equity Research
Tandem Diabetes Care (TNDM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
t:slim X2's Compatibility With Lilly's Lyumjev Might Aid TNDM Stock
by Zacks Equity Research
By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality.
TNDM Stock Likely to Gain From Innovation Amid Competition
by Zacks Equity Research
Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition.
TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EU
by Zacks Equity Research
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union.
Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now
by Zacks Equity Research
Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.
New Launches Support Tandem Diabetes Stock Despite Macro Concerns
by Zacks Equity Research
The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.
Medtronic (MDT) Progresses in CGM With New Approval, Alliance
by Zacks Equity Research
The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.
Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised
by Zacks Equity Research
Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 12.96% and 7.50%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical (NARI) delivered earnings and revenue surprises of -156.25% and 1.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's How Thermo Fisher (TMO) is Placed Ahead of Q2 Earnings
by Zacks Equity Research
Strength in Analytical Instrument and Laboratory Products and Services segments is likely to have driven Thermo Fisher's (TMO) second-quarter 2024 performance.
Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?
by Zacks Equity Research
In EMEA, Boston Scientific (BSX) is expected to have registered growth within structural heart, including Transcatheter aortic valve replacement, WATCHMAN and other interventional cardiology therapies.
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences' (EW) TMTT segment's PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi
by Zacks Equity Research
Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes
Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report?
by Zacks Equity Research
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM).
Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor
by Zacks Equity Research
Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.
Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance.
Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View
by Zacks Equity Research
Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
Tandem Diabetes Care (TNDM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Tandem Diabetes Care (TNDM) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 21.25% and 10.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?